Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) Expected to Announce Earnings of -$0.26 Per Share
Analysts expect Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) to post earnings of ($0.26) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Aevi Genomic Medicine’s earnings, with the highest EPS estimate coming in at ($0.17) and the lowest estimate coming in at ($0.32). Aevi Genomic Medicine posted earnings of ($0.35) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 25.7%. The business is expected to report its next quarterly earnings report on Thursday, August 3rd.
According to Zacks, analysts expect that Aevi Genomic Medicine will report full year earnings of ($1.10) per share for the current fiscal year, with EPS estimates ranging from ($1.29) to ($0.88). For the next financial year, analysts forecast that the company will report earnings of ($1.46) per share, with EPS estimates ranging from ($1.85) to ($1.12). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Aevi Genomic Medicine.
Aevi Genomic Medicine (NASDAQ:GNMX) last announced its quarterly earnings data on Wednesday, May 10th. The biotechnology company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by $0.02.
Several research firms have recently weighed in on GNMX. Needham & Company LLC reissued a “buy” rating and issued a $9.00 target price (down from $12.00) on shares of Aevi Genomic Medicine in a report on Tuesday, March 21st. Jefferies Group LLC downgraded Aevi Genomic Medicine from a “buy” rating to a “hold” rating and reduced their target price for the company from $10.00 to $2.50 in a report on Tuesday, March 21st. Finally, ValuEngine downgraded Aevi Genomic Medicine from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd.
Shares of Aevi Genomic Medicine (GNMX) traded down 1.50% on Friday, hitting $1.31. The stock had a trading volume of 238,034 shares. The company’s market cap is $48.61 million. The stock has a 50 day moving average price of $1.28 and a 200-day moving average price of $3.31. Aevi Genomic Medicine has a 12-month low of $0.98 and a 12-month high of $17.75.
In related news, Director Sol J. Barer purchased 100,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 26th. The shares were purchased at an average price of $1.54 per share, for a total transaction of $154,000.00. Following the transaction, the director now directly owns 507,000 shares of the company’s stock, valued at approximately $780,780. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 24.80% of the company’s stock.
A number of institutional investors have recently modified their holdings of the stock. State Street Corp boosted its position in shares of Aevi Genomic Medicine by 15.4% in the fourth quarter. State Street Corp now owns 345,698 shares of the biotechnology company’s stock valued at $1,789,000 after buying an additional 46,149 shares during the period. TIAA CREF Investment Management LLC boosted its position in shares of Aevi Genomic Medicine by 16.7% in the first quarter. TIAA CREF Investment Management LLC now owns 97,719 shares of the biotechnology company’s stock valued at $182,000 after buying an additional 13,966 shares during the period. Birchview Capital LP boosted its position in shares of Aevi Genomic Medicine by 41.7% in the first quarter. Birchview Capital LP now owns 68,000 shares of the biotechnology company’s stock valued at $126,000 after buying an additional 20,000 shares during the period. Finally, Teachers Advisors LLC bought a new position in shares of Aevi Genomic Medicine during the fourth quarter valued at about $204,000. Hedge funds and other institutional investors own 27.87% of the company’s stock.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aevi Genomic Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.